Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Bernichon E, Vallard A, Wang Q, Attignon V, Pissaloux D, Bachelot T, Heudel PE, Ray-Coquard I, Bonnet E, de la Fouchardière A, Faure C, Chopin N, Beurrier F, Racadot S, Sunyach MP, Rancoule C, Perol D, Corset V, Agrapart V, Tinquaut F, Blay JY, Magné N, Trédan O. Bernichon E, et al. Among authors: perol d. Ann Oncol. 2017 Nov 1;28(11):2773-2779. doi: 10.1093/annonc/mdx488. Ann Oncol. 2017. PMID: 28945826 Free article.
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.
Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay JY. Gelderblom H, et al. Among authors: perol d. Lancet Oncol. 2018 May;19(5):639-648. doi: 10.1016/S1470-2045(18)30143-8. Epub 2018 Mar 20. Lancet Oncol. 2018. PMID: 29571946 Clinical Trial.
Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial.
Foucaut AM, Morelle M, Kempf-Lépine AS, Baudinet C, Meyrand R, Guillemaut S, Metzger S, Bourne-Branchu V, Grinand E, Chabaud S, Pérol D, Carretier J, Berthouze SE, Reynes E, Perrier L, Rebattu P, Heudel PE, Bachelot T, Bachmann P, Fervers B, Trédan O, Touillaud M. Foucaut AM, et al. Among authors: perol d. Support Care Cancer. 2019 Sep;27(9):3449-3461. doi: 10.1007/s00520-019-4658-y. Epub 2019 Jan 24. Support Care Cancer. 2019. PMID: 30680617 Clinical Trial.
A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma.
Marec-Berard P, Dalban C, Gaspar N, Brugieres L, Gentet JC, Lervat C, Corradini N, Castex MP, Schmitt C, Pacquement H, Tabone MD, Brahmi M, Metzger S, Blay JY, Pérol D; OSII Thiotepa study group of the French Society of Pediatric Cancer - La Société Française des Cancers de l’Enfant (SFCE) and the French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) Networks. Marec-Berard P, et al. Among authors: perol d. Eur J Cancer. 2020 Jan;125:58-68. doi: 10.1016/j.ejca.2019.11.007. Epub 2019 Dec 12. Eur J Cancer. 2020. PMID: 31838406 Clinical Trial.
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres†.
Ghesquières H, Dalban C, Nicolas-Virelizier E, Jardin F, Le Bras F, Le Gouill S, Casasnovas O, Vizoso S, Hernandez C, Metzger S, Pérol D, Cartron G. Ghesquières H, et al. Among authors: perol d. Br J Haematol. 2021 Feb;192(3):e94-e98. doi: 10.1111/bjh.17279. Epub 2021 Jan 9. Br J Haematol. 2021. PMID: 33421031 Clinical Trial. No abstract available.
Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub-analysis of the ProfiLER protocol.
Rowinski E, Magné N, Fayette J, Daguenet E, Racadot S, Pommier P, Méry B, Vallard A, Tinquaut F, Neidhardt-Berard EM, Cassier P, Attignon V, Pissaloux D, Wang Q, Sohier E, Pérol D, Blay JY, Trédan O. Rowinski E, et al. Among authors: perol d. Head Neck. 2021 Dec;43(12):3899-3910. doi: 10.1002/hed.26891. Epub 2021 Oct 13. Head Neck. 2021. PMID: 34643313
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, Chakiba C, You B, Lancry-Lecomte L, Garin G, Marcel V, Diaz JJ, Treilleux I, Pérol D, Fabbro M, Ray-Coquard I. Heudel P, et al. Among authors: perol d. JAMA Oncol. 2022 Jul 1;8(7):1001-1009. doi: 10.1001/jamaoncol.2022.1047. JAMA Oncol. 2022. PMID: 35551299 Free PMC article. Clinical Trial.
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
Spierenburg G, Grimison P, Chevreau C, Stacchiotti S, Piperno-Neumann S, Le Cesne A, Ferraresi V, Italiano A, Duffaud F, Penel N, Metzger S, Chabaud S, van der Heijden L, Pérol D, van de Sande MAJ, Blay JY, Gelderblom H. Spierenburg G, et al. Among authors: perol d. Eur J Cancer. 2022 Sep;173:219-228. doi: 10.1016/j.ejca.2022.06.028. Epub 2022 Aug 3. Eur J Cancer. 2022. PMID: 35932628 Free article. Clinical Trial.
191 results